Lymphoma News and Research

RSS
Lymphoma is cancer that begins in cells of the immune system. There are two basic categories of lymphomas. One kind is Hodgkin lymphoma, which is marked by the presence of a type of cell called the Reed-Sternberg cell. The other category is non-Hodgkin lymphomas, which includes a large, diverse group of cancers of immune system cells. Non-Hodgkin lymphomas can be further divided into cancers that have an indolent (slow-growing) course and those that have an aggressive (fast-growing) course. These subtypes behave and respond to treatment differently. Both Hodgkin and non-Hodgkin lymphomas can occur in children and adults, and prognosis and treatment depend on the stage and the type of cancer.
Constitutive BAK/MCL1 complexes could predict sensitivity of chemotherapy drugs, research shows

Constitutive BAK/MCL1 complexes could predict sensitivity of chemotherapy drugs, research shows

Study reveals how two separate DNA changes may predict aggressive childhood leukemias

Study reveals how two separate DNA changes may predict aggressive childhood leukemias

Researchers develop method to preserve high-quality cultured stem cells for a long time

Researchers develop method to preserve high-quality cultured stem cells for a long time

Study: Biomarker can predict response to immunotherapies in breast cancer patients

Study: Biomarker can predict response to immunotherapies in breast cancer patients

Nanobody mapping using NMR proves a promising alternative for therapeutic use

Nanobody mapping using NMR proves a promising alternative for therapeutic use

Cancer cells re-organize DNA structure to ramp up the activity of oncogenes

Cancer cells re-organize DNA structure to ramp up the activity of oncogenes

Small molecular changes can have dramatic impact on the CAR T cell function

Small molecular changes can have dramatic impact on the CAR T cell function

Low representation of minority groups in genomic databases may impact therapy selection

Low representation of minority groups in genomic databases may impact therapy selection

Engineered safety switch reduces CAR-T immunotherapy-related side effects

Engineered safety switch reduces CAR-T immunotherapy-related side effects

Research links blood-clotting protein with CNS B-cell lymphoma growth

Research links blood-clotting protein with CNS B-cell lymphoma growth

Tumor microenvironment could improve cancer immunotherapy

Tumor microenvironment could improve cancer immunotherapy

New understanding of tumor microenvironment could help enhance immunotherapy

New understanding of tumor microenvironment could help enhance immunotherapy

Researchers discover new molecular mechanism that promotes cell migration

Researchers discover new molecular mechanism that promotes cell migration

Researchers create molecular ON-OFF switches to regulate CAR T cell activity

Researchers create molecular ON-OFF switches to regulate CAR T cell activity

Scientists find new way to prevent cancer relapse after immunotherapy

Scientists find new way to prevent cancer relapse after immunotherapy

Tumor DNA in DLBCL patient's stem cells or blood can predict risk of relapse after transplant

Tumor DNA in DLBCL patient's stem cells or blood can predict risk of relapse after transplant

Study: CAR T cell therapy is a safe, effective therapy for high-risk large B-cell lymphoma

Study: CAR T cell therapy is a safe, effective therapy for high-risk large B-cell lymphoma

Mice infused with CD5-deleted CAR T cells showed significant reduction in tumor size

Mice infused with CD5-deleted CAR T cells showed significant reduction in tumor size

CAR T-cell therapy reduced cancer cells in patients with advanced non-Hodgkin lymphoma

CAR T-cell therapy reduced cancer cells in patients with advanced non-Hodgkin lymphoma

Protein interactions could serve as therapeutic targets to treat viral infections

Protein interactions could serve as therapeutic targets to treat viral infections

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.